Rare Disease Day at the NIH: Why Advocacy Matters in the Future of Innovation

By Kendall Davis

Rare Disease Day at the NIH is always a powerful reminder of how far the rare disease field has come, and how much work still lies ahead.

Hosted by the NIH’s National Center for Advancing Translational Sciences (NCATS), the annual event brings together patients, researchers, regulators, industry leaders, and advocates who are all working toward the same goal: accelerating progress for people living with rare diseases.

During this year’s event, Joni Rutter, Director of NCATS, captured the moment in a way that has stayed with me. She noted that “Rare Disease Day is where our science meets accountability.”

It’s a simple statement, but an important one.

Scientific breakthroughs are accelerating across the rare disease landscape, from genomic discovery to gene editing and precision medicine. But those advances only translate into meaningful progress when the systems that support research, regulation, and development work together responsibly.

As a Board Member of Team Telomere, these conversations resonate deeply. Team Telomere supports individuals and families affected by telomere biology disorders, rare genetic conditions that impact cellular aging and can lead to serious complications including bone marrow failure, pulmonary fibrosis, and liver disease.

For families living with these conditions, progress in research is not abstract. It represents the possibility of better treatments, improved care, and ultimately therapies that do not yet exist.

One of the most striking themes at this year’s Rare Disease Day was the continued sense of urgency across the ecosystem.

Scientific advances in genomics, gene editing, and precision medicine are rapidly expanding what may be possible for rare diseases. At the same time, regulatory conversations are evolving to consider how development pathways can better reflect the realities of extremely small patient populations.

Recent discussions from the FDA, including potential single-study approvals and the introduction of a “Plausible Mechanism” framework for ultra-rare diseases, reflect an effort to address these challenges and accelerate innovation.

For many rare disease communities, that urgency is deeply meaningful. Patients facing progressive conditions often do not have the luxury of long development timelines.

But speed alone is not enough.

From my vantage point working with patient advocacy organizations and through my role with Team Telomere, I have seen how much effort rare disease communities invest in building the foundations that make research possible in the first place.

Patient advocacy organizations are not simply support networks. They are often the infrastructure behind rare disease research.

They fund early scientific exploration when traditional funding is unavailable.

They help build natural history studies and patient registries that become foundational to clinical programs.

They connect researchers with patient communities and help identify practical barriers that could affect trial participation.

In many cases, they are helping to build the knowledge and networks that allow therapies to be developed at all.

Because of this, advocacy organizations often have a unique vantage point on the research ecosystem. They see where scientific progress is accelerating, and where practical challenges remain.

That is why continued collaboration between regulators and patient advocacy organizations is so important as the regulatory landscape evolves.

Regulatory innovation is necessary. Rare disease science is advancing rapidly, and regulatory frameworks must evolve alongside it.

But as Dr. Rutter’s comment reminds us, innovation must also be paired with accountability.

Those frameworks will be strongest when they are developed in close dialogue with the patient advocacy community that has helped build the rare disease ecosystem.

Organizations like Team Telomere bring valuable insights into disease burden, research priorities, and community readiness for clinical trials. These perspectives can help inform trial feasibility, endpoint relevance, and the broader context in which therapies will ultimately be used.

Rare Disease Day demonstrates what is possible when patients, researchers, regulators, and industry work together.

But collaboration cannot be limited to a single event each year.

As new regulatory frameworks continue to take shape, ongoing engagement between the FDA and the patient advocacy community will be essential. Transparency, communication, and shared accountability will help ensure that regulatory innovation strengthens the rare disease ecosystem rather than creating uncertainty.

The rare disease community has spent decades building the scientific, clinical, and advocacy infrastructure that now makes accelerated innovation possible.

Organizations like Team Telomere, along with countless others across the rare disease landscape, have helped lay the groundwork that allows researchers, regulators, and industry sponsors to pursue therapies that once seemed out of reach.

Rare disease patients cannot wait.

But the future of rare disease innovation will depend on maintaining the partnerships that have brought the field this far, and ensuring that patient advocacy organizations remain central collaborators in shaping what comes next.